Alteris Therapeutics, Inc.
Therapeutics and vaccines (CDX-110) against novel, proprietary cancer targets. Acquired by Celldex Therapeutics in 2005, which merged with Avant Immunotherapeutics in 2008.
Exited Portfolio Company
Therapeutics and vaccines (CDX-110) against novel, proprietary cancer targets. Acquired by Celldex Therapeutics in 2005, which merged with Avant Immunotherapeutics in 2008.
Exited Portfolio Company